CanBridge Bio: Board of Directors Approves Use of Up to HK$200 Million to Repurchase Company Common Shares on the Open Market
36Kr reports that Akeso BioPharmaceuticals' board of directors has approved a share buyback program of up to HK$200 million. The company believes the current stock price does not reflect its intrinsic value and future prospects, making it an opportune time for the repurchase. The shares will be purchased by a trustee of the company's 2021 Restricted Share Unit Plan. AI